CA
NZ
UK
AU
IND
US
…
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
XORTX Therapeutics Inc (NASDAQ: XRTX) is a small biopharmaceutical firm with limited public disclosure about its pipeline. Long-term growth may be driven by clinical and regulatory milestones, strategic collaborations, and potential commercialization of any successful candidates. Investors may find exposure to early-stage drug development upside attractive, while outcomes depend heavily on trial results.
Material risks include high clinical and regulatory uncertainty, a frequent need for external financing that may dilute shareholders, limited operating history and competition in development areas.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -2.66M | -3.15M | -2.16M | -6.99M | -1.30M |
| Net income | -2.66M | -3.15M | -2.16M | -6.99M | -1.30M |
| Selling general administrative | 1.83M | 2.28M | 2.23M | 2.29M | 1.58M |
| Selling and marketing expenses | - | 1.74M | 1.76M | - | - |
| Gross profit | -0.11M | -0.11M | -0.14M | - | - |
| Reconciled depreciation | 0.11M | 0.12M | 0.14M | 0.06M | 0.02M |
| Ebit | -3.26M | -3.92M | -6.05M | -10.69M | -4.14M |
| Ebitda | -3.14M | -3.81M | -5.91M | -10.63M | -4.12M |
| Depreciation and amortization | 0.11M | 0.11M | 0.14M | 0.06M | 0.01M |
| Operating income | -3.26M | -3.92M | -6.05M | -10.69M | -4.14M |
| Other operating expenses | 3.26M | 3.92M | 6.05M | 9.86M | 2.86M |
| Interest expense | - | - | - | 0.00M | 0.00M |
| Interest income | 0.04M | 0.12M | 0.26M | 0.10M | - |
| Net interest income | 0.04M | 0.12M | 0.25M | -0.83M | -1.63M |
| Income tax expense | - | - | -0.00M | 0.00M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 3.26M | 3.81M | 6.05M | 9.86M | 2.86M |
| Cost of revenue | 0.11M | 0.11M | 0.14M | - | - |
| Total other income expense net | 0.60M | 0.77M | 3.89M | 3.70M | 2.84M |
| Net income from continuing ops | -2.66M | -3.31M | -2.16M | -6.99M | -1.65M |
| Net income applicable to common shares | - | - | - | -9.49M | -1.65M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2.68M | 4.09M | 5.47M | 12.34M | 17.28M |
| Intangible assets | 0.19M | 0.18M | 0.18M | 0.20M | 0.20M |
| Other current assets | 0.02M | 0.19M | - | - | 0.71M |
| Total liab | 0.60M | 0.76M | 0.83M | 5.37M | 4.16M |
| Total stockholder equity | 2.08M | 3.34M | 4.64M | 6.97M | 13.13M |
| Other current liab | 0.17M | 0.64M | 0.09M | 0.15M | 3.83M |
| Common stock | 20.15M | 18.49M | 17.06M | 15.18M | 15.69M |
| Capital stock | 20.18M | 18.49M | 17.06M | 15.18M | 20.01M |
| Retained earnings | -23.78M | -21.17M | -17.85M | -14.13M | -7.60M |
| Other liab | - | - | - | 5.22M | 4.60M |
| Other assets | - | - | - | 0.00M | 0.00M |
| Cash | 0.86M | 2.47M | 3.45M | 10.41M | 14.79M |
| Total current liabilities | 0.60M | 0.76M | 0.29M | 1.51M | 4.16M |
| Net debt | -0.83M | -2.43M | -3.44M | -10.33M | -14.79M |
| Short term debt | 0.04M | 0.04M | 0.01M | 0.07M | - |
| Short long term debt total | 0.04M | 0.04M | 0.01M | 0.08M | - |
| Other stockholder equity | - | 0.02M | 5.49M | 5.92M | 5.03M |
| Property plant equipment | - | - | - | 0.13M | - |
| Total current assets | 0.97M | 2.68M | 4.07M | 10.87M | 15.82M |
| Net tangible assets | - | - | - | 9.20M | 16.48M |
| Net receivables | 0.08M | 0.02M | 0.06M | 0.08M | 0.04M |
| Accounts payable | 0.40M | 0.08M | 0.20M | 1.30M | 0.32M |
| Accumulated other comprehensive income | 5.72M | 5.99M | -0.05M | - | - |
| Non currrent assets other | 0.29M | 1.20M | 1.20M | 1.18M | 1.26M |
| Non current assets total | 1.71M | 1.42M | 1.40M | 1.48M | 1.46M |
| Capital lease obligations | 0.04M | 0.04M | 0.01M | 0.08M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.04M | -0.05M | -0.04M | -0.04M |
| Change to liabilities | - | - | - | 1.26M | -0.33M |
| Total cashflows from investing activities | -0.30M | -0.04M | -0.05M | -0.06M | -0.04M |
| Net borrowings | -0.09M | -0.07M | -0.07M | -0.06M | -0.06M |
| Total cash from financing activities | 1.45M | 2.78M | -0.36M | 4.74M | 19.18M |
| Change to operating activities | - | - | - | 0.76M | -1.01M |
| Net income | -2.70M | -3.31M | -2.16M | -6.99M | -1.30M |
| Change in cash | -1.73M | -0.97M | -6.99M | -3.48M | 14.65M |
| Begin period cash flow | 2.59M | 3.45M | 10.43M | 13.89M | 0.13M |
| End period cash flow | 0.86M | 2.47M | 3.45M | 10.41M | 14.79M |
| Total cash from operating activities | -2.82M | -3.68M | -6.58M | -8.82M | -4.75M |
| Issuance of capital stock | 2.26M | 3.50M | 0.00M | 5.05M | 22.80M |
| Depreciation | 0.11M | 0.12M | 0.11M | 0.06M | 0.01M |
| Other cashflows from investing activities | -0.24M | -0.00M | -0.05M | - | - |
| Change to account receivables | -0.06M | 0.04M | 0.00M | -0.04M | -0.03M |
| Other cashflows from financing activities | -0.00M | -0.74M | -0.30M | -0.27M | 1.30M |
| Change to netincome | - | - | - | -4.52M | -3.05M |
| Capital expenditures | 0.00M | 0.04M | 0.05M | 0.04M | 0.03M |
| Change in working capital | 0.34M | 0.12M | -1.03M | 1.45M | -1.08M |
| Stock based compensation | 0.03M | 0.12M | 0.12M | 0.47M | 0.39M |
| Other non cash items | -0.59M | -0.72M | -3.62M | -3.80M | -2.78M |
| Free cash flow | -2.82M | -3.72M | -6.63M | -8.86M | -4.79M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| XRTX XORTX Therapeutics Inc |
-0.01 0.99% |
1.00 | - | 0.96 | - | 0.60 | 0.09 |
| NVO Novo Nordisk A/S |
-0.24 0.61% |
40.20 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-21.28 3.85% |
531.87 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
12.10 1.26% |
973.36 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
| Name | Title | Year Born |
|---|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, CEO, Pres & Director | 1960 |
| Mr. Amar Keshri C.A., CPA | Chief Financial Officer | 1979 |
| Nick Rigopoulos | Director of Communications | NA |
| Dr. David Sans M.B.A., Ph.D. | Director of Corp. Devel. | NA |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer | 1951 |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations | 1963 |
| Dr. Stacy Evans M.B.A., M.D. | Chief Bus. Officer | NA |
| Ms. Charlotte May | Corp. Sec. | NA |
| Dr. Allen Warren Davidoff Ph.D. | Founder, CEO, President & Director | 1960 |
| Mr. James Neville Fairbairn C.A., C.P.A., ICD.D | Interim Chief Financial Officer | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...